Chinanews.com, Lanzhou, September 19 (Shi Jingjing) How to improve biomedical innovation capabilities?
What is the industry goal?
What are the difficulties in the development of biomedicine?
On the afternoon of the 19th, the 2020 4th China Biomedical Park Industry Innovation and Development Conference and the 3rd Lanzhou Independent Innovation Forum were held. Hundreds of experts from across the country exchanged ideas and provided suggestions for the development of biomedicine.
The conference was hosted by the Biomedical Park Development Alliance of China Technology Entrepreneurship Association, Lanzhou High-tech Zone Management Committee, and green catalysis expert think tank to explore new trends, new changes and new opportunities in the biomedical industry in the post-epidemic era.
"The biomedical industry cluster has strong R&D strength, large industrial scale, and sufficient development potential." Zhang Mu, deputy director of the Torch Center of the Ministry of Science and Technology, said that the national biomedical industry focuses on the national high-tech zone and has deployed 25 biomedical innovative types. Industrial clusters.
According to statistics in 2018, the total industrial output value of 169 national high-tech zone biomedical companies reached 1.8 trillion yuan.
The picture shows the promotion of biomedical industry in Lanzhou High-tech Zone.
Photo by Yin Chunyong
Shi Liqiang, vice president of the Chinese Society for Drug Administration, said that the biomedicine segment in the post-epidemic era will usher in major development opportunities. How to achieve a long-term layout in the domestic industrial cycle of the biomedical industry is an important opportunity now.
The biomedical industry has the characteristics of high investment, high risk, high return, and long research and development cycle.
Therefore, agglomeration development is an effective way to enhance industrial competitiveness.
And Daochang, secretary-general of the China Technology Entrepreneurship Association, put forward suggestions at this meeting: the high-tech zones in Gansu, Sichuan, Yunnan and other provinces where traditional Chinese medicine is developed, the combination of traditional Chinese medicine industry and modern biomedical technology may improve the traditional Chinese medicine industry. The level has a certain effect.
He Mingyuan, academician of the Chinese Academy of Sciences and chief scientist of national green chemistry, is very optimistic about the development prospects of biomedicine.
He said that it will be an inevitable trend to improve drug R&D and mass production, accelerate the synthesis of green medicine innovation, and promote the development of the green medicine industry.
"The direction of biomedicine development in Lanzhou is particularly correct." He Mingyuan said, I believe that biomedical scientists can find a "useful place" in Lanzhou and in the west.
Lanzhou High-tech Zone is the first nationally created zone approved for construction in an underdeveloped area in western China, and has 12 national key laboratories.
Relying on Gansu's rich medical resources and concentrated scientific research capabilities, biomedicine is listed as the first industry, forming an industrial cluster with biopharmaceuticals, biotechnology, and biohealth.
The picture shows the staff of Gansu Longshen Rongfa Pharmaceutical Co., Ltd. packing medicines in the production workshop.
(Data map) Gao Zhanshe
Sun Yu, director of the Management Committee of Lanzhou High-tech Zone, revealed his "family status" at the opening of the meeting.
He said that what is not known to everyone is that 60% of the national foot-and-mouth disease vaccine market share is produced in the Lanzhou High-tech Zone, and there are also "national teams" such as Zhongsheng Biological and China Animal Husbandry.
There are more than 200 biomedical companies in the region, with a total output value of 14.2 billion yuan last year.
Sun Yu said frankly that there are currently no "unicorn" high-tech enterprises, which is the pain point of the development of Lanzhou Biomedicine.
Therefore, they have "published hero posts widely" and provided subsidies for R&D innovation and the transformation of scientific research results, with individual rewards up to 10 million yuan.
Sun Yu said that the Lanzhou High-tech Zone is now positioned as a "pioneer bull" in the demonstration zone for industry-city integration.
Based on the reality of Gansu, we adhere to the concept of “inheriting the past, and innovating without leaving the clan”, adhere to both inheritance and innovation, give full play to the latecomer advantages of the high-tech zone, and promote the development of biomedicine.
In his speech, Wu Heqian, the deputy mayor of Lanzhou, said that in recent years, Lanzhou has strengthened the full-process professional services from front-end R&D to production, built a biomedical industrial park with high standards, and made every effort to build a biomedical innovation and development base in the northwest and even the country. I hope that experts and scholars will express their opinions. Use innovative ideas to make suggestions for Lanzhou, pass the scriptures and send treasures.
(Finish)